The US Bankruptcy Court gave an order granting the conversion of Chapter 11 reorganization of Sienna Biopharmaceuticals, Inc. to liquidation under Chapter 7 on December 18, 2019. As per the motion filed by debtor, the debtor’s available cash and proceeds of the sale are not sufficient to repay the prepetition lender in full.